Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Clearside Biomedical price target raised to $17 from $15 at Roth Capital » 20:09
10/25/21
10/25
20:09
10/25/21
20:09
CLSD

Clearside Biomedical

$5.60 /

-0.125 (-2.19%)

, RGNX

Regenxbio

$36.56 /

+0.63 (+1.75%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Clearside Biomedical (CLSD) to $17 from $15 and keeps a Buy rating on the shares after the company announced the approval of XIPERE, or the suprachoroidally-delivered Triamcinolone. This marks the first approval for a product delivered with its SCS injector, which derisks its use for the delivery of multiple other agents such as REGENXBIO's (RGNX) anti-VEGF gene therapy RGX-314 and Aura Biosciences' virus-like drug conjugate AU-011, Jallah tells investors in a research note.

ShowHide Related Items >><<
RGNX Regenxbio
$36.56 /

+0.63 (+1.75%)

CLSD Clearside Biomedical
$5.60 /

-0.125 (-2.19%)

CLSD Clearside Biomedical
$5.60 /

-0.125 (-2.19%)

10/04/21 Roth Capital
Clearside injector de-risked by Regenxbio data, says Roth Capital
07/29/21 H.C. Wainwright
Clearside Biomedical initiated with a Buy at H.C. Wainwright
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
06/18/21 Roth Capital
Clearside Biomedical price target raised to $15 from $9 at Roth Capital
RGNX Regenxbio
$36.56 /

+0.63 (+1.75%)

10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
RGNX Regenxbio
$36.56 /

+0.63 (+1.75%)

CLSD Clearside Biomedical
$5.60 /

-0.125 (-2.19%)

  • 08
    Jan
CLSD Clearside Biomedical
$5.60 /

-0.125 (-2.19%)

Over a week ago
Initiation
Regenxbio assumed with an Overweight at Morgan Stanley » 08:19
10/19/21
10/19
08:19
10/19/21
08:19
RGNX

Regenxbio

$35.37 /

-0.62 (-1.72%)

, ABBV

AbbVie

$107.42 /

-1.94 (-1.77%)

Morgan Stanley analyst…

Morgan Stanley analyst Vikram Purohit assumed coverage of Regenxbio (RGNX) with an Overweight rating with a price target of $50, down from $62. He expects the near-term focus to be on RGX-314 for retinal disease, adding that he views recent data updates and the partnership with AbbVie (ABBV) "highly encouraging."

ShowHide Related Items >><<
RGNX Regenxbio
$35.37 /

-0.62 (-1.72%)

ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

RGNX Regenxbio
$35.37 /

-0.62 (-1.72%)

10/04/21 Roth Capital
Clearside injector de-risked by Regenxbio data, says Roth Capital
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
07/09/21 Chardan
Regenxbio coverage transferred at Chardan
ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RGNX Regenxbio
$35.37 /

-0.62 (-1.72%)

ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

  • 08
    Jan
ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

ABBV AbbVie
$107.42 /

-1.94 (-1.77%)

Conference/Events
Lineage Cell Therapeutics management to meet virtually with B. Riley » 04:55
10/18/21
10/18
04:55
10/18/21
04:55
LCTX

Lineage Cell Therapeutics

$2.35 /

-0.035 (-1.47%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by B. Riley.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

LCTX Lineage Cell Therapeutics
$2.35 /

-0.035 (-1.47%)

Hot Stocks
Apellis, Sobi: Aspaveli receives positive CHMP opinion » 07:38
10/15/21
10/15
07:38
10/15/21
07:38
APLS

Apellis

$35.45 /

+1.52 (+4.48%)

Swedish Orphan Biovitrum…

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals announce that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli for the treatment of adults with paroxysmal nocturnal haemoglobinuria who are anaemic after treatment with a C5 inhibitor for at least three months. The positive opinion from the CHMP is now referred to the European Commission for an approval decision.

ShowHide Related Items >><<
APLS Apellis
$35.45 /

+1.52 (+4.48%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

10/01/21 Jefferies
Apellis' pecetacoplan has approvable profile in GA, says Jefferies
10/01/21 Cantor Fitzgerald
Cantor sees 'high likelihood' of approval for Apellis in geographic atrophy
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/13/21 Baird
Apellis price target lowered to $75 from $80 at Baird
APLS Apellis
$35.45 /

+1.52 (+4.48%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

Hot Stocks
Apellis, Sobi receive positive CHMP opinion for Aspaveli » 07:18
10/15/21
10/15
07:18
10/15/21
07:18
APLS

Apellis

$35.45 /

+1.52 (+4.48%)

, BIOVF

Swedish Orphan Biovitrum

$27.13 /

+0.265 (+0.99%)

Apellis Pharmaceuticals…

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF)) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are anemic after treatment with a C5 inhibitor for at least three months. The positive opinion from the CHMP is now referred to the European Commission for an approval decision. The positive opinion is based on the results from the head-to-head Phase 3 PEGASUS study, which evaluated the efficacy and safety of Aspaveli compared to eculizumab at 16 weeks in adults with PNH who had persistent anemia despite treatment with eculizumab. The results were published in the New England Journal of Medicine in March 2021.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$27.13 /

+0.265 (+0.99%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

10/01/21 Jefferies
Apellis' pecetacoplan has approvable profile in GA, says Jefferies
10/01/21 Cantor Fitzgerald
Cantor sees 'high likelihood' of approval for Apellis in geographic atrophy
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/13/21 Baird
Apellis price target lowered to $75 from $80 at Baird
BIOVF Swedish Orphan Biovitrum
$27.13 /

+0.265 (+0.99%)

07/23/21 Barclays
Swedish Orphan Biovitrum price target raised to SEK 160 from SEK 155 at Barclays
07/22/21 Pareto
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto
07/21/21 Deutsche Bank
Swedish Orphan Biovitrum upgraded to Buy from Hold at Deutsche Bank
05/05/21 DNB Markets
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets
APLS Apellis
$35.45 /

+1.52 (+4.48%)

BIOVF Swedish Orphan Biovitrum
$27.13 /

+0.265 (+0.99%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

APLS Apellis
$35.45 /

+1.52 (+4.48%)

Conference/Events
Lineage Cell Therapeutics management to meet virtually with B. Riley » 09:39
10/11/21
10/11
09:39
10/11/21
09:39
LCTX

Lineage Cell Therapeutics

$2.41 /

-0.04 (-1.63%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by B. Riley.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

LCTX Lineage Cell Therapeutics
$2.41 /

-0.04 (-1.63%)

Hot Stocks
Coherus Biosciences announces passing of board member Alan Mendelson » 08:42
10/11/21
10/11
08:42
10/11/21
08:42
CHRS

Coherus Biosciences

$18.04 /

+0.46 (+2.62%)

Coherus BioSciences…

Coherus BioSciences announces the unexpected passing of board member Alan Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010. Mendelson served as a partner at Latham & Watkins LLP from May 2000 to December 2020, where he held several leadership roles, including Co-Chair of the Emerging Companies Practice Group and Global Co-Chair of the Life Sciences Industry Group, and advised numerous private and public companies, primarily in the life sciences industry.

ShowHide Related Items >><<
CHRS Coherus Biosciences
$18.04 /

+0.46 (+2.62%)

CHRS Coherus Biosciences
$18.04 /

+0.46 (+2.62%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
CHRS Coherus Biosciences
$18.04 /

+0.46 (+2.62%)

Hot Stocks
Regenxbio presents initial data from Phase II ALTITUDE trial of RGX-314 » 15:23
10/10/21
10/10
15:23
10/10/21
15:23
RGNX

Regenxbio

$31.69 /

-0.78 (-2.40%)

Regenxbio announced…

Regenxbio announced initial data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy without center-involved diabetic macular edema using in-office suprachoroidal delivery. ALTITUDE is a multi-center, open-label, randomized, controlled dose-escalation trial that will evaluate the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using the SCS Microinjector in patients with a DR diagnosis of moderately severe or severe nonproliferative diabetic retinopathy or mild proliferative diabetic retinopathy. Twenty patients in Cohort 1 were randomized to receive RGX-314 at a dose level of 2.5x1011 genomic copies per eye versus observational control at a 3:1 ratio. Cohort 2 will include 20 patients randomized to receive RGX-314 at an increased dose level of 5x1011 GC/eye versus observational control at a 3:1 ratio. Cohort 3 is designed to evaluate RGX-314 at the same dose level as Cohort 2 in 20 patients who are neutralizing antibody positive. Enrollment is ongoing in Cohorts 2 and 3. Patients in this trial do not receive prophylactic immune suppressive corticosteroid therapy before or after administration of RGX-314. As of September 29, 2021, RGX-314 was reported to be well tolerated in the 15 patients dosed with RGX-314 in Cohort 1. One serious adverse event was reported in one patient dosed with RGX-314, which occurred in the patient's untreated fellow eye and is considered not related to RGX-314. Among patients in Cohort 1 dosed with RGX-314, no intraocular inflammation was observed on slit-lamp examination. One patient experienced a mild case of episcleritis that resolved with topical corticosteroids. Common ocular treatment emergent adverse events in the study eye were not considered drug-related and were predominantly mild. These included conjunctival hemorrhage and conjunctival hyperemia. Of the 15 patients dosed with RGX-314 in Cohort 1, five patients demonstrated a two-step or greater improvement from baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale at three months, compared to zero of the five patients in the observational control group. One patient dosed with RGX-314 had a four-step improvement. In the seven patients who had NPDR at baseline, three patients demonstrated a two-step or greater improvement at three months after administration of RGX-314. In the eight patients who had PDR at baseline, two patients demonstrated a two-step or greater improvement at three months after administration of RGX-314.

ShowHide Related Items >><<
RGNX Regenxbio
$31.69 /

-0.78 (-2.40%)

RGNX Regenxbio
$31.69 /

-0.78 (-2.40%)

10/04/21 Roth Capital
Clearside injector de-risked by Regenxbio data, says Roth Capital
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
07/09/21 Chardan
Regenxbio coverage transferred at Chardan
RGNX Regenxbio
$31.69 /

-0.78 (-2.40%)

  • 08
    Jan
Conference/Events
Lineage Cell Therapeutics management to meet with  12:35
10/08/21
10/08
12:35
10/08/21
12:35
LCTX

Lineage Cell Therapeutics

$2.44 /

-0.01 (-0.41%)

Meeting to be held

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

LCTX Lineage Cell Therapeutics
$2.44 /

-0.01 (-0.41%)

Hot Stocks
Coherus Biosciences announces results of UNDENYCA OBI clinical trial » 08:20
10/05/21
10/05
08:20
10/05/21
08:20
CHRS

Coherus Biosciences

$15.81 /

-0.685 (-4.15%)

Coherus BioSciences…

Coherus BioSciences announced "positive" results from a randomized, open-label, crossover study assessing the pharmacokinetic, PK, and pharmacodynamic, PD, bioequivalence of UDENYCA administered via a proprietary on-body injector, OBI, device compared to the currently marketed UDENYCA pre-filled syringe. The study met all PK bioequivalence primary endpoints as well as the key secondary pharmacodynamic endpoint of ANC. No new safety signals were observed. The study enrolled 189 subjects randomized 1:1 to receive one of two treatment sequences of UDENYCA: OBI followed by PFS, or the reverse, with a treatment interval of 6 to 8 weeks. Coherus plans a 2022 submission to the United States Food and Drug Administration of a prior approval supplement to seek marketing authorization for the UDENYCA OBI and anticipates a standard 10-month review period. Coherus expects commercial launch of the UDENYCA OBI directly post approval. "UDENYCA quickly became the top-selling pre-filled syringe pegfilgrastim in the U.S. within months of launch in 2019, establishing Coherus as a trusted partner to oncologists and demonstrating the power of biosimilar competition to expand patient access to an important cancer medicine," said Denny Lanfear, CEO of Coherus. "With our OBI program progress, we are excited by the potential to offer to providers and patients a new on-body injector presentation of UDENYCA, if approved, and to compete directly with Neulasta Onpro, which retains more than 50% share of the overall pegfilgrastim market."

ShowHide Related Items >><<
CHRS Coherus Biosciences
$15.81 /

-0.685 (-4.15%)

CHRS Coherus Biosciences
$15.81 /

-0.685 (-4.15%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
CHRS Coherus Biosciences
$15.81 /

-0.685 (-4.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.